📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
MedPlus Seeks Shareholder Nod for ₹11,262.20 Mn Related Party Transaction with Subsidiary
MedPlus Health Services has initiated a postal ballot to seek shareholder approval for material related party transactions (RPT) with its subsidiary, Optival Health Solutions Private Limited. The proposed transactions for the financial year 2026-27 are capped at an aggregate value of ₹11,262.20 million. This approval is mandatory under SEBI regulations as the transaction value exceeds 10% of the company's annual consolidated turnover. The e-voting period for shareholders is scheduled from February 25 to March 26, 2026.
Key Highlights
Proposed RPT with material subsidiary Optival Health Solutions for FY 2026-27.
Aggregate transaction limit set at ₹11,262.20 million plus applicable taxes.
Transactions exceed the 10% materiality threshold of annual consolidated turnover.
Remote e-voting period runs from February 25, 2026, to March 26, 2026.
Board confirms transactions are in the ordinary course of business and at arm’s length.
💼 Action for Investors
Investors should note this as a standard regulatory compliance procedure for large-scale inter-company operations; no immediate portfolio changes are recommended.
MedPlus Q3 FY26: Strong 10%+ SSSG and 182 Net Store Additions Drive Growth
MedPlus Health Services reported a robust Q3 FY26 with consolidated revenue of ₹1,806.1 crore and an operating EBITDA of ₹96.8 crore (5.4% margin). A key highlight was the recovery in Same Store Sales Growth (SSSG) to over 10%, attributed to revised store-level incentive structures and better product availability. The company added 182 net stores during the quarter, bringing the total network to 5,112, and remains on track for its 600-store annual target. The diagnostics segment also showed healthy growth with revenue reaching ₹32.67 crore and margins improving to 15.5%.
Key Highlights
Achieved 10%+ Same Store Sales Growth (SSSG) following strategic tweaks to store incentive structures.
Net addition of 182 stores in Q3, reaching a total network of 5,112 stores across 2.6 million sq. ft.
Private label pharma GMV share reached 18.9%, a significant jump from 7.9% in the prior year's first quarter.
Diagnostics segment revenue grew to ₹326.7 million with an improved operating EBITDA margin of 15.5%.
Consolidated EBITDA of ₹96.8 crore includes a non-recurring charge of ₹7.06 crore for new Labour Code implementation.
💼 Action for Investors
Investors should view the return to double-digit SSSG and the scaling of the high-margin diagnostics business as positive indicators of operational efficiency. Monitor the upcoming full-scale rollout of the franchisee model as a potential catalyst for capital-light expansion in FY27.
MedPlus Subsidiary Faces IT Dept Review Petition Over ₹43.45 Cr Tax Dispute
MedPlus Health Services' subsidiary, Optival Health Solutions, is facing a review petition from the Income Tax Department regarding a ₹43.45 crore tax dispute for AY 2020-21. Previously, the Telangana High Court had ruled in favor of the company, effectively removing the financial liability. However, the IT Department's filing of a review petition on December 23, 2025, reopens the case. While there is no immediate financial impact, the resolution of this ₹43.45 crore matter is now subject to further judicial outcome.
Key Highlights
Income Tax Department filed a review petition against a favorable High Court order dated Nov 21, 2025
The dispute involves a tax amount of ₹43.45 Crores for Assessment Year 2020-21
The litigation concerns the company's subsidiary, Optival Health Solutions Private Limited
Company received intimation of the review petition filing on January 07, 2026
💼 Action for Investors
Investors should monitor the progress of this review petition as it brings a previously resolved ₹43.45 crore tax liability back into focus. No immediate action is required as the company has previously won the writ petition in the High Court.
Medplus Promoter Unpledges 41.72 Lakh Shares; Group Pledge Drops to 24.48%
Agilemed Investments Private Limited, a promoter of Medplus Health Services, has released the pledge on 41,71,970 equity shares, representing approximately 3.48% of the total share capital. This release follows the completion of a debt refinancing transaction and the repayment of existing non-convertible debentures (NCDs). Consequently, the aggregate promoter group pledge has decreased from a temporary high of 27.96% to 24.48%. While the reduction is positive, the total promoter group still has 60.74% of their holding encumbered.
Key Highlights
Agilemed Investments released 41,71,970 pledged shares on December 24, 2025, following debt repayment.
Aggregate promoter group pledge reduced from 27.96% to 24.48% of the total share capital.
The release was triggered by the retirement of NCDs worth approximately ₹321 crore issued to Modulus Alternatives.
Total promoter holding stands at 40.29%, with 2.93 crore shares (60.74% of their stake) still pledged.
The market value of the released shares was approximately ₹342.23 crore based on the price of ₹820.30 per share.
💼 Action for Investors
The reduction in pledged shares is a positive development indicating successful debt refinancing and repayment by the promoters. However, investors should remain cautious as the overall promoter pledge remains high at over 60% of their total stake.
Medplus Promoter Pledges 4.05% Stake to Refinance ₹175 Crore Debt
Agilemed Investments, a promoter of Medplus Health Services, has pledged 48.51 lakh shares (4.05% of total capital) to refinance existing debt. This transaction is part of a debt restructuring where the promoter group's total pledged holding will temporarily rise to 27.96% before settling at an expected 24.48% once old pledges are released. Currently, a significant 69.39% of the total promoter stake is encumbered. The ₹175 crore raised via Non-Convertible Debentures (NCDs) will be used specifically to retire existing promoter-level debt.
Key Highlights
Agilemed Investments pledged 48,51,066 shares, representing 4.05% of the company's total share capital.
Total promoter encumbrance stands at 69.39% of their holding, which exceeds the 50% threshold for disclosure.
The pledge was created in favor of Catalyst Trusteeship for a ₹175 crore NCD issuance to refinance existing debt.
Aggregate promoter group pledge is expected to eventually reduce to 24.48% of total capital post-refinancing.
The newly pledged shares were valued at approximately ₹388.89 crore based on a price of ₹801.65 per share.
💼 Action for Investors
Investors should remain cautious as high promoter pledging (nearly 70% of their stake) can lead to volatility if share prices drop significantly. Monitor the successful release of old pledges to ensure the aggregate encumbrance reduces as planned.
MedPlus Promoters to Refinance ₹175 Cr Debt; Temporary Share Pledge Increase to 27.96%
Promoters of MedPlus Health Services, including MD & CEO Gangadi Madhukar Reddy, have executed a Debenture Trust Deed to issue NCDs worth up to ₹175 crore. The funds are intended to refinance existing debt of the promoter entity, Agilemed Investments. As a result, the promoter group's share pledge will temporarily increase from 23.91% to 27.96% during the transition. Once the existing debt is settled and shares are released, the pledge is expected to stabilize at 24.48%.
Key Highlights
Promoters to issue Non-Convertible Debentures (NCDs) worth up to ₹175 crore
NCDs carry an interest rate of 12.72% per annum plus an initial 1% coupon
Promoter share pledge to temporarily rise from 23.91% to 27.96% during refinancing
Expected post-refinancing pledge level to settle at 24.48%
Promoters currently hold a total of 40.29% equity in the company
💼 Action for Investors
Investors should monitor the timely reduction of the share pledge back to the projected 24.48% level. While refinancing is routine, the high proportion of pledged promoter shares (over 60% of their holding) warrants caution regarding potential volatility.
MedPlus subsidiary receives suspension orders for drug licenses
MedPlus Health Services' subsidiary, Optival Health Solutions, received three suspension orders for drug licenses in Maharashtra. The suspensions relate to stores in Amravati and Nagpur. The potential revenue loss due to the Amravati store suspension is approximately ₹5.96 lacs for five days. The Nagpur store suspensions could result in revenue losses of ₹2.57 lacs and ₹1.64 lacs respectively, each also for five days.
Key Highlights
Suspension of Drug License for five days of a store situated at Irwin Square Amravati, Maharashtra.
Potential Revenue Loss of Rs~5.96 lacs from Amravati store suspension.
Suspension of Drug License for five days each of stores in Sakkardara and Untkhana Road, Nagpur, Maharashtra.
Potential Revenue Loss of Rs~2.57 lacs from Sakkardara store suspension.
Potential Revenue Loss of Rs~1.64 lacs from Untkhana Road store suspension.
💼 Action for Investors
Investors should monitor the impact of these suspensions on MedPlus's overall revenue and profitability. Watch for further updates from the company regarding the resolution of these regulatory issues.
Medplus subsidiary Optival Health Solutions receives favorable order
MedPlus Health Services announced that its subsidiary, Optival Health Solutions Private Limited, received a favorable order from the Hon’ble High Court of Telangana. The order relates to a writ petition filed against an Assessment Order for AY 2020-21, which disputed a tax amount of ₹43.45 Crores. The High Court allowed the writ petition, resulting in no financial impact on the company. This development resolves a contingent liability and removes uncertainty for investors.
Key Highlights
Optival Health Solutions Private Limited received a favorable order.
The order relates to Assessment Year 2020-21.
The disputed tax amount was ₹43.45 Crores.
The Telangana High Court allowed the writ petition.
💼 Action for Investors
Investors should view this as a positive development as it resolves a tax dispute and removes a potential financial burden. Monitor MedPlus's financial statements for any further updates related to this order.
Medplus Subsidiary Receives Favorable Order from Telangana High Court
Optival Health Solutions Private Limited, a subsidiary of Medplus, has received a favorable order from the Hon’ble High Court of Telangana regarding a writ petition. The petition was related to an Assessment Order for AY:2020-21, concerning a disputed tax amount of ₹43.45 Crores. The High Court allowed the writ petition, resulting in no financial impact on Medplus. This development resolves a prior legal challenge and removes uncertainty related to the disputed tax assessment.
Key Highlights
Favorable order received from the High Court of Telangana on 21.11.2025
Disputed tax amount of ₹43.45 Crores for AY:2020-21
Order received on 23.11.2025
Writ petition allowed by the Telangana High Court
💼 Action for Investors
Investors can view this as a positive development as it resolves a tax dispute. Monitor Medplus's website for further details.